Skip to main content

A team approach to treating type 1 diabetes with Fiasp®

See 4 health care professionals discuss how open communication
can make a difference when treating patients.

A team approach to treating type 1 diabetes with Fiasp®

See 4 health care professionals discuss how open communication can make a difference when treating patients.

Team approach
Why Fiasp®
Providing a team approach for caring for patients with T1D

Patients with T1D face their condition nonstop, every day. While daily routines can make T1D treatment more manageable; life does not always work that way. Patients face uncertainty regarding when and how much they will eat, in addition to life’s daily distractions.

Listen as 4 health care professionals share how they support their patients’ individual diabetes treatment goals and struggles by prescribing Fiasp® as a mealtime insulin.

Watch this team’s approach to treatment
Discover why the team prescribes Fiasp®
Get patients involved in their care
Patients ask: "Why me?" and, "What have I done?" And it's nothing that they've done; it is not “Why me?”, it's, "Here's what we can do, here's how we can take care of this." And we have to go that direction, get them to the point that they understand what they're doing and let them be involved in their care.
Randy Jerkins, PharmD Pharmacist
Discover why the team prescribes Fiasp®
Return to overview
Why I chose Fiasp® for my patients
They're living with diabetes every day, every minute of the day, 365 days a year. And [think about] every time they see [their blood sugar] go high post-meal. If I were type 1, I would want a fast insulin.
Bruce W Bode, MD, FACE Endocrinologist
Watch this team’s approach to treatment
Return to overview

Meet the care team

Randy Jerkins, PharmD

Pharmacist
Williamson Medical Center

Believes educating patients and their families is key to successfully managing T1D

Bruce W. Bode, MD, FACE

Endocrinologist
Atlanta Diabetes Associates

One of the lead investigators on the clinical trials for Fiasp®

Terri Jerkins, MD

Endocrinologist
Williamson Medical Center

Nearly 80% of Terri’s patients have type 1 diabetes

Joseph Johnson, PA-C

Physician Assistant
Atlanta Diabetes Associates

Has extensive experience with clinical studies and prescribing insulin

Meet the care team

Bruce W. Bode, MD, FACE

Endocrinologist
Atlanta Diabetes Associates

One of the lead investigators on the clinical trials for Fiasp®

Randy Jerkins, PharmD

Pharmacist
Williamson Medical Center

Believes educating patients and their families is key to successfully managing T1D

Terri Jerkins, MD

Endocrinologist
Williamson Medical Center

Nearly 80% of Terri’s patients have type 1 diabetes

Joseph Johnson, PA-C

Physician Assistant
Atlanta Diabetes Associates

Has extensive experience with clinical studies and prescribing insulin

The breadth of Fiasp® formulary coverage may surprise you

Affordability programs and offers to help patients save on their insulin

Novo Nordisk is committed to helping your patients with type 1 diabetes throughout their treatment with support and access to insulin no matter what type of insurance they have, or even if they are without insurance. Through NovoCare®, we can help your patients find programs that may lower the cost of their insulin Fiasp® or provide it free if they qualify.

Direct patients to NovoCare.com/letushelp to get help with costs.

Affordability programs and offers to help patients save on their insulin

Novo Nordisk is committed to helping your patients with type 1 diabetes throughout their treatment with support and access to insulin no matter what type of insurance they have, or even if they are without insurance. Through NovoCare®, we can help your patients find programs that may lower the cost of their insulin Fiasp® or provide it free if they qualify.

Direct patients to NovoCare.com/letushelp to get help with costs.

Are you interested in trying Fiasp®?

Are you interested in trying Fiasp®?

Get complimentary samples of Fiasp® for your appropriate patients.

Selected Important Safety Information

Contraindications

  • Fiasp® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Fiasp® or one of its excipients.

Warnings and Precautions

  • Never share a Fiasp® FlexTouch® Pen, PenFill® cartridge or PenFill® cartridge device between patients, even if the needle is changed. Patients using Fiasp® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
  • Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.

Fiasp® (insulin aspart injection) 100 U/mL Indications and Usage

Fiasp® (insulin aspart injection) 100 U/mL is a rapid-acting insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Important Safety Information

Contraindications

  • Fiasp® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Fiasp® or one of its excipients.

Warnings and Precautions

  • Never share a Fiasp® FlexTouch® Pen, PenFill® cartridge or PenFill® cartridge device between patients, even if the needle is changed. Patients using Fiasp® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
  • Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia. Make any changes to a patient’s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. Adjustments in concomitant anti-diabetic treatment may be needed.
  • Hypoglycemia is the most common adverse reaction of insulin, including Fiasp®, and may be life-threatening. Increase glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness.
  • To avoid medication errors and accidental mix-ups between Fiasp® and other insulin products, instruct patients to always check the insulin label before injection.
  • As with all insulins, Fiasp® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including Fiasp®.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Fiasp®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered.
  • Pump or infusion set malfunctions can lead to a rapid onset of hyperglycemia and ketoacidosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Interim therapy with subcutaneous injection of Fiasp® may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

Adverse Reactions

  • Adverse reactions observed with Fiasp® include hypoglycemia, allergic reactions, hypersensitivity, injection site reactions, lipodystrophy, and weight gain.

Use in Specific Populations

  • Pediatric patients with type 1 diabetes treated with mealtime and postmeal Fiasp® reported a higher rate of blood glucose confirmed hypoglycemic episodes compared to patients treated with NovoLog® (insulin aspart injection); the imbalance was greater during the nocturnal period. Monitor blood glucose levels closely in pediatric patients.
  • Like all insulins, Fiasp® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments.

Please click here for Prescribing Information.